Innate and Myeloid Research
Solutions Accelerated by IsoPlexis
- TLR Therapeutics
- Multiple Sclerosis Progression
- Macrophage Differentiation
Monocyte polyfunction in MS tracks differential responses to treatments for early diagnosis and early intervention1
Uncover the polyfunctional immune cell subsets which correlate to biomarkers of response in autoimmune diseases.
Identify differences in mechanism for Multiple Sclerosis patients in response to novel therapeutics, such as TLR2 therapy
PSI reveals key differences in monocyte response to TLR2, in patients with MS
Additionally, PSI correlated as an indicator of on treatment/off treatment response in MS patients
Identification of enhanced MS response to TLR2 stimulation through IsoPlexis’ PSI. CD14+ monocyte PSI was calculated for control (n=8) and MS patient samples (n=8) stimulated for 24 hours with P3C (TLR2 stimulation). The PSI of the MS patients samples was notably higher than in the control samples; the PSI of both sample groups was dominated by polyfunctional IL-8 secretions.
Statistical analysis showed that the PSI of the MS patients (mean = 34) are statistically higher (p = 0.0348) than the PSI of the control samples (mean = 14). The level of PSI representing the upper threshold of control responses (based on the control IQR) is depicted by the dashed line. The percent of responses above threshold is depicted for controls and total MS patients. The difference in PSI between the two groups suggests an important role of TLR2 signaling in mediating MS disease progress.